Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Getty ImagesA team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Early findings suggest that IA tenecteplase after successful thrombectomy is safe and improves functional outcomes over standard care in anterior circulation LVO stroke.

LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive ...

Injecting tenecteplase into the artery after clot removal helps improve recovery in stroke survivors, leading to better ...